|Day Low/High||36.37 / 36.80|
|52 Wk Low/High||33.97 / 46.47|
Pfizer Inc. (NYSE: PFE) announced today positive preliminary results following administration of three doses in a four-dose series for a Proof-of-Concept Phase 2 study (B7471003) to assess safety and immunogenicity of its 20-valent pneumococcal conjugate...
Mark Hulbert takes a look at the stocks most favored by the top-performing newsletters.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Chief Financial Officer and Executive Vice President, Global Supply and Business Operations, at the Morgan Stanley 17 th Annual Global...
Stocks finish higher as energy stocks rise on the back of higher oil prices.
Stocks finish down as recession worries again emerge and as investors monitor U.S. and China trade negotiations.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Jim Cramer takes a look at Union Pacific, Pfizer, Merck, AbbVie, Teva Pharmaceuticals, ABM Industries, Schlumberger and more.
XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.
Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina.
There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.
A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #20 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #299 spot.
The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.
Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints.
Pfizer Inc. (NYSE: PFE) today announced the closing of its joint venture with GlaxoSmithKline plc (NYSE: GSK) to combine the parties' respective consumer healthcare businesses to create the world's largest over-the-counter (OTC) business with robust...
Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.
Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
Pfizer reports earnings and announces a massive tie-up with Mylan, sending shares of the latter shooting higher.
What new management means for Mylan shareholders moving forward.
Jim Cramer weighs in on Pfizer and Mylan, Starbucks and, of course, the causes for a week of market madness.
Mylan and Pfizer agreed to combine their off-patent drug businesses in an all-stock deal that will create a new company based in the United States.
Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.
Pfizer is in talks to merge its off-patent drug operation with Mylan.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.